TLDR:
- Merck signed a $2 billion licensing agreement with China’s Jiangsu Hengrui Pharmaceuticals for heart disease drug HRS-5346
- This continues a trend of U.S. drugmakers seeking innovations from Chinese firms at lower investment costs
- Merck is being evaluated as a potential defensive stock amid current market volatility
- Healthcare is considered a strong defensive sector due to long-term demographic trends and favorable industry outlook
- Merck will pay $200 million upfront, with up to $1.77 billion in milestone payments for the drug that’s currently in mid-stage trials
Merck & Co. has made headlines with its latest strategic move in the pharmaceutical industry. The company recently signed a licensing agreement worth up to $2 billion with China-based Jiangsu Hengrui Pharmaceuticals for a promising heart disease medication.
This deal, announced on Tuesday, gives Merck exclusive rights to develop, manufacture, and sell the experimental oral heart disease drug HRS-5346 worldwide, except in the Greater China region. The drug is currently progressing through mid-stage clinical trials in China.
Under the agreement terms, Merck will pay an upfront payment of $200 million. Hengrui Pharma will be eligible for up to $1.77 billion in additional payments if certain development, regulatory, and commercial milestones are met.
HRS-5346 belongs to a class of drugs that prevent the formation of cholesterol, fats, and proteins in the blood. These substances can limit blood flow to vital organs, potentially resulting in heart attacks, strokes, and other cardiovascular diseases.
This acquisition represents Merck’s continued strategy of partnering with Chinese biotechnology firms. Analysts note that major pharmaceutical companies are increasingly turning to Chinese biotechs for innovative drugs at lower investment costs.
Merck has been actively pursuing this approach. Last year, the company signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma’s experimental oral drug to treat obesity.
They also purchased the rights to an early-stage cancer drug from China’s LaNova in a deal valued at up to $3.3 billion. This pattern demonstrates Merck’s commitment to expanding its drug pipeline through strategic international partnerships.
Merck as a Defensive Investment
Beyond its business development activities, Merck is also being evaluated for its potential as a defensive stock amid current market volatility. Defensive stocks typically provide stability during economic uncertainty and market turbulence.
Healthcare has been highlighted by investment experts as a potentially strong defensive sector. According to a March report by T. Rowe Price, healthcare benefits from long-term demographic trends, a favorable cyclical outlook in healthcare tools, and improving industry structure in biotechnology.
These characteristics make healthcare companies like Merck attractive to investors seeking protection against market downturns. Companies with consistent earnings, strong financials, and a history of resilience can help navigate market uncertainties more effectively.
Experts stress the importance of defensive positioning in the current market environment. Adam Parker, CEO of Trivariate Research, recently emphasized that market positioning and expectations are currently misaligned.
He noted that many investors have turned bearish, but believes there hasn’t been enough of a positioning shakeout to justify turning bullish yet. Parker highlighted that upcoming earnings guidance from companies will be crucial in determining market direction.
The Chinese Connection
China continues to be an interesting source of pharmaceutical innovations at lower costs, according to Kevin Gade, chief operating officer at Bahl & Gaynor, which owns Merck shares. This trend extends beyond Merck to other major players in the industry.
Danish drugmaker Novo Nordisk recently purchased global rights to China-based United Laboratories International’s weight-loss drug candidate in a deal worth up to $2 billion. Eli Lilly has also been active in seeking partnerships with Chinese biotechnology firms.
These deals reflect the growing importance of Chinese innovation in the global pharmaceutical landscape. They also demonstrate how major pharmaceutical companies are adapting their business models to access promising drug candidates while managing investment costs.
Merck’s latest deal for HRS-5346 represents both a strategic expansion of its cardiovascular portfolio and a continuation of its approach to leveraging international partnerships for growth. The company’s activities position it at the intersection of business development and potential defensive investment characteristics.
As market volatility continues and economic uncertainties persist, Merck’s combination of strategic growth initiatives and position in the defensive healthcare sector may offer investors an interesting option to consider in their portfolio construction.
Stay Ahead of the Market with Benzinga Pro!
Want to trade like a pro? Benzinga Pro gives you the edge you need in today's fast-paced markets. Get real-time news, exclusive insights, and powerful tools trusted by professional traders:
- Breaking market-moving stories before they hit mainstream media
- Live audio squawk for hands-free market updates
- Advanced stock scanner to spot promising trades
- Expert trade ideas and on-demand support
